Key result
Trimetazidine significantly improved left ventricular ejection fraction compared to placebo (34.4% vs 27.0%, p<0.0001) at 6 months in elderly patients with ischaemic cardiomyopathy.
Why the study?
Does trimetazidine improve left ventricular function in elderly patients with ischaemic heart disease and reduced LV function?
Population
47 elderly patients with ischaemic heart disease and reduced left ventricular function
Comparison
Trimetazidine in addition to standard therapy vs Placebo in addition to standard therapy
Design
RCT, Randomised
Follow-up
6 months
Authors
Loading...
Supports trimetazidine addition in elderly ischaemic cardiomyopathy; extends metabolic modulation evidence for systolic function.
RCT (n=47)
randomised
Does trimetazidine improve left ventricular function in elderly patients with ischaemic heart disease and reduced LV function?
Absolute Event Rate: 34.4% vs 27%
p-value: p=<0.0001
Trimetazidine added to standard therapy significantly improves left ventricular systolic and diastolic function, as well as quality of life, in elderly patients with ischaemic cardiomyopathy.
Vitale et al. (2004) conducted an RCT in ischaemic heart disease and reduced LV function (n=47). Trimetazidine vs. Placebo was evaluated on Left ventricular ejection fraction (LVEF) (p=<0.0001). Trimetazidine significantly improved left ventricular ejection fraction compared to placebo (34.4% vs 27.0%, p<0.0001) at 6 months in elderly patients with ischaemic cardiomyopathy.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: